Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for LAURUSLABS
Revenue projections for LAURUSLABS

Laurus Labs Limited is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 0.000000
forwardPE 53.985573
debtToEquity 60.048000
earningsGrowth 12.130000
revenueGrowth 0.314000
grossMargins 0.546400
operatingMargins 0.169020
trailingEps 9.470000
forwardEps 23.370000

LAURUSLABS's forward PE ratio being too high suggests the stock's future gains could be limited, with a potential for price correction. It's critical to weigh this alongside other key fundamental parameters for a comprehensive assessment.
Laurus Labs Limited's positive earnings and revenue growth signal that the company is expected to expand its business. This healthy financial trend reflects an optimistic outlook, suggesting continued growth in both sales and profits for Laurus Labs Limited.
LAURUSLABS's forward EPS is higher than its trailing EPS, suggesting the company is expected to see an increase in profitability this year. This points to positive growth, indicating that LAURUSLABS is projected to improve its financial performance compared to the previous year.

Price projections:

Price projections for LAURUSLABS
Price projections for LAURUSLABS

LAURUSLABS's price projections have been revised upward over time, suggesting that analysts are becoming more confident in the company's future. This trend points to increased optimism about LAURUSLABS's ability to grow.

Recommendation changes over time:

Recommendations trend for LAURUSLABS
Recommendations trend for LAURUSLABS


Analysts have recently developed a sell bias for LAURUSLABS, suggesting caution when making investment decisions. Investors are advised to rely on a broad range of market indicators rather than solely on this bias to ensure a more comprehensive understanding of the stock's potential before taking action.